Story Summary: As President and CEO, Dr. Lammers is responsible for driving fundamental biological discoveries in the field of microRNA (miRNA) by the Mirna team into the clinic to ultimately become new therapeutics. We are excited to have recruited Paul to the position of CEO, as he brings broad executive, commercial, clinical and regulatory experience in the pharmaceutical and biotech industry to Mirna, stated Matt Winkler, Ph. Based on Mirnas intellectual property portfolio, Mirna will play a key role in these efforts. More than 600 miRNAs are encoded in the human genome and comprise approximately 2% of all mammalian genes. By coordinating the expression of multiple genes, miRNAs are responsible for guiding proper embryonic development, immunity, inflammation, as well as cellular growth and proliferation. Mis-regulation of miRNAs appears to play a fundamental role in many cancers and replacement of down regulated miRNAs in tumor cells may result in a positive therapeutic response, MicroRNA Replacement Therapy. About Mirna TherapeuticsMirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. Mirna scientists, while at Ambion, filed two very broad patent applications in 2004 naming more than 200 miRNAs and their functional roles in a number of different disease states. Mirna owns more than thirty pending patent applications as well as exclusive rights to pending patents submitted by Yale University. mirnarx….Read the Full Story

Related posts:

1. Mirna Therapeutics Presents Data at Keystone Symposium on MicroRNA and Cancer
2. Regulus Therapeutics Appoints Hubert C. Chen, M.D., Vice President of Translational Medicine
3. Mirna Therapeutics Announces Dr. Frank Slack as Scientific Advisor
4. Mirna Therapeutics Announces Dr. Frank Slack as Scientific Advisor
5. Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development